Study to Evaluate Treatment Effects Associated With the NeuroStar SoftStart Treatment Feature

Inclusion Criteria

• 1. 22-70 years.
• 2. Subject qualifies to receive TMS Therapy with the NeuroStar Advanced Therapy System to treat Major Depressive Disorder (MDD) per current FDA-cleared treatment guidelines as evaluated by the treating physician.
• Subject has MDD diagnosis according to applicable DSM-IV, DSM-IV-TR, DSM-V, ICD-9, or ICD-10 criteria.
• Subject failed to respond to at least one prior anti-depressant medication. 5. Subject consented to receive TMS Therapy to treat MDD with his or her physician independent of potential participation in this clinical study.
• Subject must agree not to take analgesic pain medication(s) within 8 hours prior to TMS therapy sessions.
• Subject provides written consent to take part in the study.

Exclusion Criteria

• 1. Subject satisfies any one or more of the contraindications for TMS Therapy per current treatment guidelines as determined by the PI.
• Physician intends to treat the subject with an off-label TMS Therapy or indication.
• Family history of seizures or epilepsy. 4. Subject has received prior TMS. 5. Subject is currently taking analgesic medication or substances which may affect their perception or sensation of pain.
• Known or suspected pregnancy.